2024-02-01 2025-01-31 false Capium Accounts Production 1.1 13828455 2024-02-01 2025-01-31 13828455 bus:AbridgedAccounts 2024-02-01 2025-01-31 13828455 bus:FRS102 2024-02-01 2025-01-31 13828455 bus:AuditExemptWithAccountantsReport 2024-02-01 2025-01-31 13828455 bus:SmallCompaniesRegimeForAccounts 2024-02-01 2025-01-31 13828455 bus:PrivateLimitedCompanyLtd 2024-02-01 2025-01-31 13828455 2024-02-01 2025-01-31 13828455 2025-01-31 13828455 bus:RegisteredOffice 2024-02-01 2025-01-31 13828455 core:WithinOneYear 2025-01-31 13828455 core:AfterOneYear 2025-01-31 13828455 1 2024-02-01 2025-01-31 13828455 bus:Director1 2024-02-01 2025-01-31 13828455 bus:Director1 2025-01-31 13828455 bus:Director1 2023-02-01 2024-01-31 13828455 bus:Director2 2024-02-01 2025-01-31 13828455 bus:Director2 2025-01-31 13828455 bus:Director2 2023-02-01 2024-01-31 13828455 2023-02-01 13828455 bus:LeadAgentIfApplicable 2024-02-01 2025-01-31 13828455 2023-02-01 2024-01-31 13828455 2024-01-31 13828455 core:WithinOneYear 2024-01-31 13828455 core:AfterOneYear 2024-01-31 13828455 bus:EntityAccountantsOrAuditors 2023-02-01 2024-01-31 13828455 bus:OrdinaryShareClass1 2024-02-01 2025-01-31 13828455 bus:OrdinaryShareClass1 2025-01-31 13828455 bus:OrdinaryShareClass1 2023-02-01 2024-01-31 13828455 bus:OrdinaryShareClass1 2024-01-31 13828455 core:ComputerEquipment 2024-02-01 2025-01-31 13828455 core:ComputerEquipment 2025-01-31 13828455 core:ComputerEquipment 2024-01-31 13828455 core:LeasedAssetsHeldAsLessee core:PlantMachinery 2025-01-31 13828455 core:LeasedAssetsHeldAsLessee core:PlantMachinery 2024-01-31 13828455 core:CostValuation core:Non-currentFinancialInstruments 2025-01-31 13828455 core:CostValuation core:Non-currentFinancialInstruments 2024-01-31 13828455 core:AdditionsToInvestments core:Non-currentFinancialInstruments 2025-01-31 13828455 core:DisposalsDecreaseInInvestments core:Non-currentFinancialInstruments 2025-01-31 13828455 core:RevaluationsIncreaseDecreaseInInvestments core:Non-currentFinancialInstruments 2025-01-31 13828455 core:Non-currentFinancialInstruments 2025-01-31 13828455 core:Non-currentFinancialInstruments 2024-01-31 13828455 core:RetainedEarningsAccumulatedLosses 2025-01-31 13828455 core:RetainedEarningsAccumulatedLosses 2024-01-31 13828455 dpl:Item1 2024-02-01 13828455 dpl:Item1 2025-01-31 13828455 dpl:Item1 2023-02-01 13828455 dpl:Item1 2024-01-31 iso4217:GBP xbrli:shares xbrli:pure
Logo On Report
Registered Number: 13828455
England and Wales

 

 

 

SAGE PHARMACEUTICALS LTD


Abridged Accounts
 


Period of accounts

Start date: 01 February 2024

End date: 31 January 2025
Accountant’s report
You consider that the company is exempt from an audit for the year ended 31 January 2025 . You have acknowledged, on the balance sheet, your responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts. These responsibilities include preparing accounts that give a true and fair view of the state of affairs of the company at the end of the financial year and of its profit or loss for the financial year.
In accordance with your instructions, we have prepared the accounts which comprise the Profit and Loss Account, the Statement of Comprehensive Income, the Balance Sheet, the Statement of Changes in Equity and the related notes from the accounting records of the company and on the basis of information and explanations you have given to us.
We have not carried out an audit or any other review, and consequently we do not express any opinion on these accounts.
Sembeh Associate Limited
31 January 2025



....................................................

Sembeh Associate Limited

350 Bastable Avenue
Barking Essex
London
IG11 0LL
14 February 2025
1
 
 
Notes
 
2025
£
  2024
£
Fixed assets      
Tangible fixed assets 3 2,500    5,000 
2,500    5,000 
Current assets      
Cash at bank and in hand 29,104    18,234 
Creditors: amount falling due within one year (27,349)   (18,991)
Net current assets 1,755    (757)
 
Total assets less current liabilities 4,255    4,243 
Net assets 4,255    4,243 
 

Capital and reserves
     
Profit and loss account 4,255    4,243 
Shareholders' funds 4,255    4,243 
 


For the year ended 31 January 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:
  1. The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476.
  2. The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts.
These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime. In accordance with Section 444 of the Companies Act 2006, the income statement has not been delivered to the Registrar of Companies.

The members have agreed to the preparation of abridged accounts for this accounting period in accordance with section 444(2A).
The financial statements were approved by the board of directors on 14 February 2025 and were signed on its behalf by:


-------------------------------
UZOMA GERALD MBAEYI
Director
2
General Information
SAGE PHARMACEUTICALS LTD is a private company, limited by shares, registered in England and Wales, registration number 13828455, registration address FLAT 2, 4 CHRIST CHURCH ROAD, SURBITON, KT5 8JJ.

The presentation currency is £ sterling.
1.

Accounting policies

Significant accounting policies
Statement of compliance
These financial statements have been prepared in compliance with FRS 102 – The Financial Reporting Standard applicable in the UK and Republic of Ireland and the Companies Act 2006.
Basis of preparation
The financial statements have been prepared under the historical cost convention as modified by the revaluation of land and buildings and certain financial instruments measured at fair value in accordance with the accounting policies.
The financial statements are prepared in sterling which is the functional currency of the company.
Turnover
Turnover comprises the invoiced value of goods and services supplied by the company, net of Value Added Tax and trade discounts.
Taxation
Taxation represents the sum of tax currently payable and deferred tax. Tax is recognised in the statement of income, except to the extent that it relates to items recognised in other comprehensive income or directly in capital and reserves.
The company’s liability for current tax is calculated using the tax rates and laws that have been enacted or substantively enacted at the reporting date.
Current and deferred tax assets and liabilities are not discounted
Dividends
Proposed dividends are only included as liabilities in the statement of financial position when their payment has been approved by the shareholders prior to the statement of financial position date.
Tangible fixed assets
Tangible fixed assets, other than freehold land, are stated at cost or valuation less depreciation and any provision for impairment. Depreciation is provided at rates calculated to write off the cost or valuation of fixed assets, less their estimated residual value, over their expected useful lives on the following basis:
Computer Equipment 25% Straight Line
2.

Average number of employees

Average number of employees during the year was 1 (2024 : 0).
3.

Tangible fixed assets

Cost or valuation Computer Equipment   Total
  £   £
At 01 February 2024 10,000    10,000 
Additions  
Disposals  
At 31 January 2025 10,000    10,000 
Depreciation
At 01 February 2024 5,000    5,000 
Charge for year 2,500    2,500 
On disposals  
At 31 January 2025 7,500    7,500 
Net book values
Closing balance as at 31 January 2025 2,500    2,500 
Opening balance as at 01 February 2024 5,000    5,000 


4.

Share Capital

Allotted, called up and fully paid
2025
£
  2024
£
1 Class A share of £1.00 each  
 

3